spacer
home > ebr > autumn 2009 > mycoplasma contamination - the invisible threat?
PUBLICATIONS
European Biopharmaceutical Review

Mycoplasma Contamination - The Invisible Threat?

 

Cell cultures are increasingly being used for the manufacture of biopharmaceutical products. Contamination of these cell cultures by mycoplasma is a fundamental problem, as it potentially compromises the safety of the drugs being produced. Therefore, biopharmaceutical production must comply with different legal requirements and regulatory bodies all over the world. Recently, new techniques for rapid and comprehensive mycoplasma detection have been developed and validated in accordance with legal guidelines, replacing the time-consuming microbiology culture methods.

MYCOPLASMA CONTAMINATIONS IN BIOPHARMA

Contamination of cell cultures by mycoplasmas is a widespread and serious problem in biological research and biopharmaceutical production. Although testing cell cultures for mycoplasmas has increased in recent decades, it has been suggested that up to 30 per cent of cell cultures in current use are still infected, including those distributed by commercial culture collections (1).

Mycoplasmas (or Mollicutes) represent a distinct class of prokaryotes which are characterised by the lack of a substantial cell wall. With a size of only 0.2 to 2μm in diameter, they are considered to be the smallest bacteria known so far. Since the first report of the detection of mycoplasma in cell culture in the 1950s, more than 100 different mycoplasma species have been identified (2). The majority of the cell culture infections are caused by only a few species. Depending on the host cell line and the cell culture matrix used for cultivation, the species Mycoplasma arginini, M hyorhinis, M hominis, M orale, M fermentans and Acholeplasma laidlawii usually represent over 90 per cent of the identified contaminants. The frequency of these species may vary due to different applications and studies. If complex cell culture matrices are used for the production of biotechnological compounds, such as avian-, insect- or plant-based material, other mycoplasma species such as M gallisepticum, M synoviae or Spiroplasma citri may also be identified (3).


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Björn Breth, PhD, obtained his Masters degree in biotechnology working on proand eukaryotic fermentation processes and drug characterisation. During his PhD thesis, he focused on microarray-based analyses and characterisation of transcription factors. He continued his scientific career developing molecular test systems for high-throughput screening in cooperation with international biotechnology and pharmaceutical companies. At Greiner Bio-One GmbH, he is responsible for the development of bacterial, viral and human identification systems for the biopharmaceutical industry. Recently, he has become a member of the FDA mycoplasma working group.
spacer
Björn Breth
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Turkish Cargo awarded with the prestigious Cargo Airline of the Year 2019 prize by the global logistics industry

 Maintaining its upward trend, Turkish Cargo was granted with the ‘Cargo Airline of the Year 2019’ award, called as the Oscar of the global logistics industry, by the global air cargo sector readers of the Air Cargo News magazine.
More info >>

White Papers

Clinical Trials in Ukraine: Orange Paper Overview and 1st Half Year 2014

Synergy Research Group

The Orange Paper is an analytical report about the clinical trials market in Russia, published quarterly by the contract research organization Synergy Research Group. The first edition of Orange Paper was released in 2006, and at the moment 31 issues have already published. Now, thanks to Synergy Group Ukraine, obtaining information about the market of clinical trials in Ukraine has become possible. In Ukraine, during the period from 1996 to 2013, applicants had obtained 3,864 positive conclusions about the possibility of conducting clinical trials of drugs, both for domestic and foreign manufacturers, including conduct of multinational multi-center clinical trials (hereinafter – MMCTs)
More info >>

 
Industry Events

World Pharma Week 2019

17-20 June 2019, Seaport World Trade Center, Boston

World Pharma Week will bring together a unique and international mix of large and medium pharmaceutical and biotech companies, CROs, leading universities and clinical research institutions, emerging companies and tool providers—making it a perfect meeting-place to share experience, foster collaborations across industry and academia, and evaluate emerging technologies.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement